NCT05743049 Collection of Circulating Biomarkers in Pancreatic Cancer
| NCT ID | NCT05743049 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Abramson Cancer Center at Penn Medicine |
| Condition | Pancreas Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 30 participants |
| Start Date | 2023-02-27 |
| Primary Completion | 2027-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 30 participants in total. It began in 2023-02-27 with a primary completion date of 2027-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This protocol will involve collection of blood samples from patients with a diagnosis of pancreatic adenocarcinoma for evaluation of circulating biomarkers.
Eligibility Criteria
Inclusion Criteria: * The subject must have a known or presumed diagnosis of pancreatic adenocarcinoma * The subject must be a patient of the University of Pennsylvania * The subject must be able to provide informed consent * The subject must be 18 years of age or older Exclusion Criteria: . Subjects who have any clinically significant psychiatric, social, or medical condition that, in the opinion of the investigator, could increase the patient's risk, interfere with protocol adherence, or affect the patient's ability to give informed consent are ineligible to participate in the study.
Contact & Investigator
Mark O'Hara, MD
PRINCIPAL INVESTIGATOR
Abramson Cancer Center, University of Pennsylvania
Frequently Asked Questions
Who can join the NCT05743049 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Pancreas Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05743049 currently recruiting?
Yes, NCT05743049 is actively recruiting participants. Contact the research team at mazali@pennmedicine.upenn.edu for enrollment information.
Where is the NCT05743049 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT05743049 clinical trial?
NCT05743049 is sponsored by Abramson Cancer Center at Penn Medicine. The principal investigator is Mark O'Hara, MD at Abramson Cancer Center, University of Pennsylvania. The trial plans to enroll 30 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.